HemoSonics

StarFish Contribution

HemoSonics developed a standalone point of care global hemostasis analysis device to provide rapid, easy to interpret assessment of overall hemostatic potential in a variety of
clinical settings. StarFish took the point of care device for clotting time testing from very early proof of concept stage to fully functional prototype including a disposable cartridge
design. StarFish developed prototype electronics, ultrasound driving circuitry, a mechanism for acoustically coupling and the injected molded disposable cartridge.

$100M Valuation

HemoSonics was acquired by Stago Group in May 2017 with a valuation in excess of $100M CAD. Stago is a leading player in the In-Vitro Diagnostics industry dedicated to the
exploration of Thrombosis and Haemostasis. The product is now marketed as HemoSonics’ Quantra® Hemostasis System.